Pegloticase

Drug Profile

Pegloticase

Alternative Names: KRYSTEXXA; Methoxypolyethylene glycol uricase; PEG urate oxidase; PEG-uricase; PEGylated uricase; Polyethylene glycol-uricase; Puricase; Urate-oxidase-PEG

Latest Information Update: 26 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Duke University; Mountain View Pharmaceuticals
  • Developer Savient Pharmaceuticals
  • Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gout
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout

Most Recent Events

  • 14 Jun 2017 Additional efficacy data from phase III trials in Gout released by Horizon Pharma
  • 11 May 2016 Horizon Pharma receives notice of allowance for a patent application related to pegloticase in USA
  • 11 May 2016 The US label for pegloticase carries a black box warning related to the risk of anaphylaxis and infusion reactions
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top